Referências: |
Barratt G, Bretagne S. Optimizing efficacy of Amphotericin B through nanomodification. International Journal of Nanomedicine. 2007;2(3):301-313.
García-Hernández R, Gómez-Pérez V, Castanys S, Gamarro F. Fitness ofLeishmania donovani Parasites Resistant to Drug Combinations. Maes L, ed.PLoS Neglected Tropical Diseases. 2015;9(4):e0003704. doi:10.1371/journal.pntd.0003704.
Mosqueira VCF, Loiseau PM, Bories C, Legrand P, Devissaguet J-P, Barratt G. Efficacy and Pharmacokinetics of Intravenous Nanocapsule Formulations of Halofantrine in Plasmodium berghei-Infected Mice. Antimicrobial Agents and Chemotherapy. 2004;48(4):1222-1228. doi:10.1128/AAC.48.4.1222-1228.2004.
Brotherton M-C, Bourassa S, Légaré D, Poirier GG, Droit A, Ouellette M. Quantitative proteomic analysis of amphotericin B resistance in Leishmania infantum. International Journal for Parasitology: Drugs and Drug Resistance. 2014;4(2):126-132. doi:10.1016/j.ijpddr.2014.05.002.
Purkait B, Kumar A, Nandi N, et al. Mechanism of Amphotericin B Resistance in Clinical Isolates of Leishmania donovani. Antimicrobial Agents and Chemotherapy. 2012;56(2):1031-1041. doi:10.1128/AAC.00030-11.
|